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IMPACT OF A 3-TIER PHARMACY BENEFIT 
ON UTILIZATION PATTERNS OF TOP 
10 THERAPEUTIC CLASSES:
A 15-MONTH FOLLOW-UP STUDY
Ara S,Yu W
WellPoint Pharmacy Management, West Hills, CA, USA
OBJECTIVES: While 3-tier pharmacy copayment struc-
ture is the most common pharmacy beneﬁt design in
2002, limited published studies examine the value of such
beneﬁt design. This study evaluated the impact of chang-
ing from a 2-tier to 3-tier pharmacy beneﬁt on drug costs,
utilization and generic utilization rates of top 10 thera-
peutic classes.
METHODS: An employer group that has changed from
a 2-tier ($5/$10) to 3-tier pharmacy beneﬁt ($5/$15/$25)
in 6/2000 and a managed health plan that has similar 2-
tier pharmacy beneﬁt and membership base were chosen
respectively as the case and control for this study. Phar-
macy claims data 12 months pre- and 15 months post 
3-tier beneﬁt implementation was evaluated. Top 10 ther-
apeutic classes (TC ranked by total drug ingredient costs
spent) of the case were identiﬁed at baseline. For each TC,
net changes in drug ingredient costs per member per
month (PMPM), drug utilization per member per year
(PMPY) and generic utilization rates from baseline were
calculated and adjusted for inherent TC trends using the
control data.
RESULTS: During the 15-month follow-up period, reduc-
tion in PMPM costs occurred in 9 out of the 10 TC, with
an average PMPM reduction of $0.36 per TC. Dramatic
reductions in PMPM costs were observed on all TCs
within 3 months post-implementation of 3-tier beneﬁt;
however, all TCs (except for acne medications) showed
increase in PMPM costs toward baseline values during 
the rest of the study period. Only modest reduction 
(0.07 PMPY) in prescription utilization was observed.
Four TCs demonstrated marked improvement in average
generic utilization rates (cephalosporins 8.7%, calcium
channel blockers 6.2%, ACE inhibitors 5.0%, acne 
products 4.1%).
CONCLUSIONS: A 3-tier pharmacy beneﬁt can reduce
pharmacy expenditures and improve generic utilization
rates of common drug classes. Further research to evalu-
ate its impact on medical costs is warranted.
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INTER-INSTITUTIONAL VARIABILITY IN
PHARMACY COSTS, LENGTH OF STAY AND
MORTALITY ASSOCIATED WITH CARDIAC
TRANSPLANTATION AT ACADEMIC HEALTH
CENTERS:A RETROSPECTIVE DATABASE
ANALYSIS
Korner EJ,Weber LA, Matuszewski KA
University HealthSystem Consortium, Chicago, IL, USA
OBJECTIVE: When ranked by inpatient pharmaceutical
cost, cardiac transplantation (DRG 103) consistently
appears among the top 10 DRGs in the University Health-
System Consortium (UHC) Clinical Database. This has
implications for pharmaceutical budgeting and managed
care contracting. The objective of this analysis was to
assess inter-institutional variability in clinical and eco-
nomic outcomes as measured by pharmacy costs, length
of stay and mortality among heart transplant patients in
UHC’s Pharmacy Clinical Database during calendar year
2000.
METHODS: Eight geographically diverse academic
health centers were identiﬁed retrospectively from all 20
UHC Pharmacy Clinical Database participants as having
submitted at least 5 heart transplant cases during calen-
dar year 2000. Institutions were assessed for variability
in pharmacy costs, length of stay (LOS) and mortality.
Data were compiled from hospital discharge summaries,
Uniform Billing Version 1992 data and charge descrip-
tion masters. Cost data were generated from converting
institution-speciﬁc charge data using a ratio of cost-to-
charges (RCC).
RESULTS: The total pharmaceutical cost for 232 patients
from 8 institutions [range = 5–96 patients/institution] was
$5,083,860. Across institutions the median pharmaceuti-
cal cost per patient, median LOS per patient and total
mortality rate were $11,509 (range = $5,697–$32,763),
22 days (range = 10.5 days–105 days), and 10.3% (range
= 0%–23.5%) respectively. Cardiovascular agents
(17.6%), biologic and immunologic agents (16.7%),
hematological agents (16.4%) and systemic anti-
infectives (10.7%) comprised over 60% of total phar-
maceutical cost. Variation in percent class cost of 
total pharmaceutical costs among institutions were
11.9%–28.4% in cardiovascular agents, 6.5%–38% in
biologic and immunologic agents, 7.1%–27.5% in 
hematological agents, and 8.1%–11.7% in systemic anti-
infectives.
CONCLUSION: There is considerable variation among
institutions in pharmacy costs, length of stay and mor-
tality. Further research into the drivers of pharmaceutical
cost variation, resource utilization and clinical outcome
is warranted.
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EVALUATION OF DRUGS IN A THREE-TIER
PRESCRIPTION DRUG BENEFIT CO-PAYMENT
PRICING STRUCTURE
Patel G, Shah S, Siganga W, Lively B, Holiday-Goodman M
The University of Toledo,Toledo, OH, USA
One of the widely used pharmacy beneﬁt management
tools, to control drug expenditures, is three-tier drug 
co-payment.
OBJECTIVES: This study examines the effect of the
three-tier drug co-payment, for the individual plan
sponsor, on Per Member Per Month (PMPM) ingredient
costs, PMPM utilization and ingredient cost per pre-
scription of the preferred and non-preferred drugs.
METHODS: Prescription records, from January 1, 1999
to December 31, 2000 for members enrolled in a three-
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tier drug beneﬁt plan at a managed care plan in Toledo-
Ohio, were reviewed retrospectively. The top ten therapy
classes based on net costs to the health plan were selected
for analysis. The records for these classes were extracted
using the Rx Clients Report v 5.0 software at the health
plan. Data were analyzed using Microsoft Excel 2000.
RESULTS: On average 1) PMPM ingredient costs
increased 16.5% for the preferred drugs and decreased
7.4% for the non-preferred drugs; 2) PMPM utilization
increased 19.3% for the preferred drugs and decreased
12.7% for the non–preferred drugs and; 3) Ingredient
cost per prescription increased 2.8% for the preferred
drugs and also increased 4.7% for the non-preferred
drugs. The increase in the PMPM ingredient costs and
PMPM utilization maybe due to the utilization of the
most expensive preferred drugs on the formulary. The
ingredient costs per prescription were not skewed either
towards the preferred or the non-preferred drugs.
CONCLUSION: The implementation of a three-tier drug
co-payment caused a decrease in the PMPM ingredient
costs and PMPM utilization of the non-preferred drugs.
It generated cost-savings to the managed care plan over
a period of two years by shifting the members from 
high cost non-preferred drugs to the lower cost preferred
drugs.
PHP30
PRACTICAL ASPECTS OF DESIGNING AND
CONDUCTING PHARMACOECONOMIC
STUDIES IN JAPAN
Doherty J, Sato K
Pharmacia Inc,Tokyo, Japan
Economic evaluation of medical technologies in Japan is
challenging because of a lack of data sources.
OBJECTIVE: This paper reviews the data sources avail-
able for conducting pharmacoeconomics research in
Japan, and discusses health policy reforms that may
increase the demand for pharmacoeconomics studies in
the future.
METHODS: A literature review of pharmacoeconomic
studies was conducted in both English (MEDLINE 
OHE-HEED) and Japanese publications (JAPICDOC) to
identify the typical data sources used in these studies.
Reﬂecting on ﬁrst hand experience conducting outcomes
research in Japan, we summarized (percent of studies 
utilizing the different data source types) and commented
on the data sources.
RESULTS: A total of 42 published studies were found 
in the Japanese and English literature from 1980–2001.
Typical sources identiﬁed for resource utilization data
included: clinical trials (62%), epidemiology/case studies
(43%), patient chart reviews (52%), expert panels (12%).
Sources for clinical efﬁcacy or disease state transition
probabilities included: clinical trials (60%), epidemiol-
ogy/case studies (36%), patient chart reviews (29%),
expert panels (12%). The cost data sources identiﬁed
were: 1) national uniform reimbursement fees (98%)—
Japanese Ministry of Health, Labor and Welfare
(MHLW), 2) micro-cost studies (2%). The MHLW
uniform fees represent costs from the health insurance
plan viewpoint, and therefore are relevant in drug price
negotiations with the MHLW. Demand for pharma-
coeconomic data may increase because of: 1) upcoming
MHLW pharmaceutical pricing and/or health insurance
system reforms; 2) new regulatory committees e.g. NICE.
CONCLUSION: Access to data sources for pharma-
coeconomic research is generally known to be limited 
in Japan, however several published studies effectively
overcame such limitations. Compared to other countries,
however, detailed population-based data are still rela-
tively unavailable. Upcoming health care reforms may
increase the demand for pharmacoeconomic data in
Japan, thus, increasing the demand for better sources of
data typically needed for these studies.
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OUTCOMES AND COSTS OF ACUTE
TREATMENT OF TRAUMATIC BRAIN INJURY
McGarry L1, Thompson D1, Millham FH2, Cowell L3,
Snyder PJ4, Lenderking W4,Weinstein MC5
1Innovus Research, Inc, Medford, MA, USA; 2Boston Medical
Center, Boston, MA, USA; 3Center for Neurological Recovery,
Newton Centre, MA, USA; 4Pﬁzer Global Research &
Development, Groton, CT, USA; 5Harvard School of Public
Health, Boston, MA, USA
OBJECTIVE: Although there are nearly a quarter of a
million hospitalizations for traumatic brain injury (TBI)
in the U.S. each year, economic data on TBI treatment are
limited. The purpose of this study was to estimate the out-
comes and costs of acute inpatient treatment of TBI.
METHODS: Using a large, geographically-diverse, multi-
hospital database, we examined inpatient records for
persons aged 16 years or older who were hospitalized for
TBI between January 1, 1997 and June 30, 1999. Patients
were stratiﬁed by TBI severity using an adaptation of 
the Abbreviated Injury Scale for administrative data
(ICD/AIS), as follows: 2, “moderate”; 3, “serious”; 4,
“severe”; and 5, “critical”. Patient characteristics, pat-
terns of treatment, and outcomes and costs were exam-
ined by injury severity and mechanism of injury. Costs of
treatment were estimated from billed charges using cost-
to-charge ratios from the Medicare Prospective Payment
System.
RESULTS: Of 8,717 study subjects identiﬁed, 12.5% had
moderate, 44.8% serious, 29.6% severe, and 13.2% 
critical TBI. Falls were the most common reported cause
of injury (40.8%), followed by motor-vehicle accidents
(39.3%), blows to the head (11.3%), and gunshot
wounds (2.4%). Average length of stay in hospital ranged
from 6.7 days for moderate TBI to 17.5 days for critical
TBI. The overall rate of death in hospital was relatively
low among patients with moderate (1.3%), serious
(5.7%), and severe (8.7%) TBIs, but much higher among
the most critically injured patients (52.0%). Costs of hos-
